The Economic Times daily newspaper is available online now.

    Shilpa Medicare gets USFDA nod for cancer treatment injection

    Synopsis

    Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

    pharma-generic
    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.
    NEW DELHI: Shilpa Medicare Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers.

    The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

    Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.

    Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million.

    Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more
    The Economic Times

    Stories you might be interested in